These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 22301630)

  • 1. Therapeutic vaccination with recombinant adenovirus reduces splenic parasite burden in experimental visceral leishmaniasis.
    Maroof A; Brown N; Smith B; Hodgkinson MR; Maxwell A; Losch FO; Fritz U; Walden P; Lacey CN; Smith DF; Aebischer T; Kaye PM
    J Infect Dis; 2012 Mar; 205(5):853-63. PubMed ID: 22301630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A lentiviral vaccine expressing KMP11-HASPB fusion protein increases immune response to Leishmania major in BALB/C.
    Mortazavidehkordi N; Fallah A; Abdollahi A; Kia V; Khanahmad H; Najafabadi ZG; Hashemi N; Estiri B; Roudbari Z; Najafi A; Farjadfar A; Hejazi SH
    Parasitol Res; 2018 Jul; 117(7):2265-2273. PubMed ID: 29845415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hybrid cell vaccination resolves Leishmania donovani infection by eliciting a strong CD8+ cytotoxic T-lymphocyte response with concomitant suppression of interleukin-10 (IL-10) but not IL-4 or IL-13.
    Basu R; Bhaumik S; Haldar AK; Naskar K; De T; Dana SK; Walden P; Roy S
    Infect Immun; 2007 Dec; 75(12):5956-66. PubMed ID: 17908806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epitope mapping and protective immunity elicited by adenovirus expressing the Leishmania amastigote specific A2 antigen: correlation with IFN-gamma and cytolytic activity by CD8+ T cells.
    Resende DM; Caetano BC; Dutra MS; Penido ML; Abrantes CF; Verly RM; Resende JM; Piló-Veloso D; Rezende SA; Bruna-Romero O; Fernandes AP; Gazzinelli RT
    Vaccine; 2008 Aug; 26(35):4585-93. PubMed ID: 18588933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterologous priming-boosting with DNA and vaccinia virus expressing kinetoplastid membrane protein-11 induces potent cellular immune response and confers protection against infection with antimony resistant and sensitive strains of Leishmania (Leishmania) donovani.
    Guha R; Das S; Ghosh J; Naskar K; Mandala A; Sundar S; Dujardin JC; Roy S
    Vaccine; 2013 Apr; 31(15):1905-15. PubMed ID: 23499564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani.
    Bhowmick S; Ravindran R; Ali N
    Infect Immun; 2008 Mar; 76(3):1003-15. PubMed ID: 18195029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis.
    Stäger S; Smith DF; Kaye PM
    J Immunol; 2000 Dec; 165(12):7064-71. PubMed ID: 11120835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cationic solid-lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice.
    Saljoughian N; Zahedifard F; Doroud D; Doustdari F; Vasei M; Papadopoulou B; Rafati S
    Parasite Immunol; 2013 Dec; 35(12):397-408. PubMed ID: 23710803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leishmania donovani serine protease encapsulated in liposome elicits protective immunity in experimental visceral leishmaniasis.
    Das P; Paik D; Naskar K; Chakraborti T
    Microbes Infect; 2018 Jan; 20(1):37-47. PubMed ID: 28970116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis.
    Basu R; Bhaumik S; Basu JM; Naskar K; De T; Roy S
    J Immunol; 2005 Jun; 174(11):7160-71. PubMed ID: 15905560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a new live recombinant vaccine against cutaneous leishmaniasis in BALB/c mice.
    Salari S; Sharifi I; Keyhani AR; Ghasemi Nejad Almani P
    Parasit Vectors; 2020 Aug; 13(1):415. PubMed ID: 32787908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies on the protective efficacy of freeze thawed promastigote antigen of Leishmania donovani along with various adjuvants against visceral leishmaniasis infection in mice.
    Thakur A; Kaur H; Kaur S
    Immunobiology; 2015 Sep; 220(9):1031-8. PubMed ID: 26001730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serodiagnostic and immunoprophylactic potential of a 78kDa protein of Leishmania donovani of Indian origin.
    Mukherjee M; Bhattacharyya A; Duttagupta S
    Med Sci Monit; 2002 Apr; 8(4):BR117-22. PubMed ID: 11951057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LmjMAPK10 offers protection against Leishmania donovani infection.
    Kumar S; Zutshi S; Patidar A; Bodhale N; Roy S; Sarkar A; Saha B
    Parasite Immunol; 2020 Feb; 42(2):e12687. PubMed ID: 31770453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
    Melby PC; Yang J; Zhao W; Perez LE; Cheng J
    Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IFN-γ
    Yadav S; Prakash J; Singh OP; Gedda MR; Chauhan SB; Sundar S; Dubey VK
    Cell Immunol; 2021 Mar; 361():104272. PubMed ID: 33445051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. To investigate the therapeutic potential of immunochemotherapy with cisplatin + 78 kDa + MPL-A against Leishmania donovani in BALB/c mice.
    Joshi J; Kaur S
    Parasite Immunol; 2014 Jan; 36(1):3-12. PubMed ID: 23964700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Live attenuated Leishmania donovani p27 gene knockout parasites are nonpathogenic and elicit long-term protective immunity in BALB/c mice.
    Dey R; Dagur PK; Selvapandiyan A; McCoy JP; Salotra P; Duncan R; Nakhasi HL
    J Immunol; 2013 Mar; 190(5):2138-49. PubMed ID: 23338240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Making an anti-amastigote vaccine for visceral leishmaniasis: rational, update and perspectives.
    Fernandes AP; Coelho EA; Machado-Coelho GL; Grimaldi G; Gazzinelli RT
    Curr Opin Microbiol; 2012 Aug; 15(4):476-85. PubMed ID: 22698479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani.
    Sukumaran B; Tewary P; Saxena S; Madhubala R
    Vaccine; 2003 Mar; 21(11-12):1292-9. PubMed ID: 12559811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.